Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

866 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. Callander NS, et al. Among authors: costello c. Blood Cancer J. 2024 Apr 22;14(1):69. doi: 10.1038/s41408-024-01030-w. Blood Cancer J. 2024. PMID: 38649340 Free PMC article. Clinical Trial.
Cross-platform proteomics signatures of extreme old age.
Reed ER, Chandler KB, Lopez P, Costello CE, Andersen SL, Perls TT, Li M, Bae H, Soerensen M, Monti S, Sebastiani P. Reed ER, et al. Among authors: costello ce. bioRxiv [Preprint]. 2024 Apr 14:2024.04.10.588876. doi: 10.1101/2024.04.10.588876. bioRxiv. 2024. PMID: 38645061 Free PMC article. Preprint.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Silbermann R, et al. Among authors: costello c. Am J Hematol. 2024 Apr 15. doi: 10.1002/ajh.27326. Online ahead of print. Am J Hematol. 2024. PMID: 38622840
Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort.
Peng Y, Kumar AV, Gu Z, Kosuru N, Wampfler JA, Reck Dos Santos PA, Yu NY, D'Cunha J, Ernani V, Costello CM, Yang P. Peng Y, et al. Among authors: costello cm. J Am Acad Dermatol. 2024 Mar 29:S0190-9622(24)00540-1. doi: 10.1016/j.jaad.2024.03.029. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38556092 No abstract available.
Platform-Specific Fc N-Glycan Profiles of an Antisperm Antibody.
Nador E, Xia C, Santangelo PJ, Whaley KJ, Costello CE, Anderson DJ. Nador E, et al. Among authors: costello ce. Antibodies (Basel). 2024 Mar 6;13(1):17. doi: 10.3390/antib13010017. Antibodies (Basel). 2024. PMID: 38534207 Free PMC article.
866 results